Printer Friendly

WATSON PHARMACEUTICALS ANNOUNCES FDA APPROVAL FOR VERAPIMIL HYDROCHLORIDE TABLET

 CORONA, Calif., July 6 /PRNewswire/ -- Watson Pharmaceuticals (NASDAQ: WATS) today announced that it has received approval from the Food and Drug Administration (FDA) for an off-patent tablet form of Verapimil Hydrochloride 40 mg. The company expects to begin shipping Verapimil Hydrochloride, a cardiovascular drug, after pre-shipment validation requirements are met.
 According to Dr. Allen Chao, president and chief executive officer, Verapimil Hydrochloride oral solid will compete with G.D. Searle's Calan(R) 40 mg. tablet. While the target market is estimated at under $10 million annually, the product represents Watson's third FDA approval in as many months and follows two recent approvals of liquid dosage forms submitted by the company.
 Watson Pharmaceuticals manufactures and distributes off-patent pharmaceuticals and is developing advanced drug delivery systems designed to enhance the therapeutic benefits of pharmaceutical compounds.
 -0- 7/6/93
 /CONTACT: Doug Sherk, Ken Dennard or Stuart Brunet, 415-296-7383; or June Filingeri or Miriam Adler, 212-850-5600, all of Morgen-Walke for Watson Pharmaceuticals/
 (WATS)


CO: Watson Pharmaceuticals ST: California IN: MTC SU:

TM-GT -- SF001 -- 8461 07/06/93 06:31 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jul 6, 1993
Words:177
Previous Article:RIO ANNOUNCES EARLY OPENING OF NEW SUITES
Next Article:TRIMBLE EXCLUSIVE SATELLITE DATA TERMINAL SUPPLIER FOR AMERICAN MOBILE SATELLITE CORPORATION
Topics:


Related Articles
WATSON PHARMACEUTICALS ANNOUNCES FDA APPROVAL FOR LOPERAMIDE HYDROCHLORIDE ORAL SOLUTION
WATSON PHARMACEUTICALS ANNOUNCES FDA APPROVAL FOR GUANFACINE-HYDROCHLORIDE TABLET
WATSON PHARMACEUTICALS ANNOUNCES FDA APPROVAL FOR ESTRADIOL TABLETS
NEW, EASY-TO-IDENTIFY ELDEPRYL(R) CAPSULE REPLACES TABLET
Somerset Initiates Legal Action Against FDA
Watson Pharmaceuticals Announces FDA Approval for NORCO(TM) 10 Mg/325 Mg Tablets
Watson Receives FDA Approval for Propafenone Hydrochloride Tablets, 150 mg and 225 mg.
Watson Receives Two FDA Approvals: Oxaprozin Tablets, 600 MG and Methylphenidate Hydrochloride ER Tablets USP, 20 MG.
Watson Receives FDA Approval for Buspirone Hydrochloride Tablets USP, 5 mg and 10 mg.
Mylan Receives FDA Approval for Metoprolol Tartrate and Hydrochlorothiazide Tablets.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters